Malik Fahmida, Hanif Malik Muhammad, Mustafa Ghulam
Department of Dermatology, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, Pakistan.
Department of Community Medicine, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, Pakistan.
J Coll Physicians Surg Pak. 2019 Jun;29(6):502-504. doi: 10.29271/jcpsp.2019.06.502.
To compare the effect of combination therapies of topical 3% tranexamic acid versus topical 20% azelaic acid each combined with oral tranexamic acid in the treatment of melasma.
Interventional comparative study.
Department of Dermatology, Sheikh Zayed Hospital, Rahim Yar Khan, from July 2017 to June 2018.
Cases of melasma diagnosed clinically (based upon history and the clinical findings of symmetrically distributed hyperpigmented macules and patches on the face), aged 12 to 50 years, were selected. The cases were divided into two groups by simple random sampling method. The cases in group A were treated by oral tranexamic acid (250 mg twice daily) with topical 3% tranexamic acid (twice daily). In group B, cases had oral tranexamic acid (250 mg twice daily) with topical 20% azelaic acid (daily) for six months. They were followed every second month upto 6 months and the efficacy was assessed on the basis of scores on MASI scale.
In 100 patient, there was no significant difference in terms of mean MASI score at 2 and 4 months with p-value of 0.20 and 0.89, respectively. However, mean MASI score was significantly less in group A (6.06 ±5.06 vs. 10.62 ±7.43) in group B (p=0.001). In group A, 14 (28%) had excellent response, whereas in group B, 11 (22%) had excellent results.
Combination of oral and topical 3% tranexamic acid is significantly better than oral tranexamic acid with 20% azelaic acid for treatment of melasma.
比较外用3%氨甲环酸与外用20%壬二酸分别联合口服氨甲环酸治疗黄褐斑的效果。
干预性对比研究。
2017年7月至2018年6月,拉希姆亚尔汗谢赫扎耶德医院皮肤科。
选取临床诊断为黄褐斑(根据病史及面部对称分布的色素沉着斑和斑片的临床特征)、年龄在12至50岁的患者。采用简单随机抽样法将患者分为两组。A组患者接受口服氨甲环酸(每日2次,每次250 mg)联合外用3%氨甲环酸(每日2次)治疗。B组患者接受口服氨甲环酸(每日2次,每次250 mg)联合外用20%壬二酸(每日1次)治疗,为期6个月。每2个月随访1次,共随访6个月,并根据MASI量表评分评估疗效。
100例患者中,2个月和4个月时平均MASI评分无显著差异,p值分别为0.20和0.89。然而,A组的平均MASI评分显著低于B组(6.06±5.06 vs. 10.62±7.43),p = 0.001。A组中14例(28%)有极佳疗效,而B组中11例(22%)有极佳疗效。
口服和外用3%氨甲环酸联合治疗黄褐斑的效果显著优于口服氨甲环酸联合20%壬二酸治疗。